The approval for interchangeability was supported by data from a phase 4 trial that assessed the pharmacokinetics, efficacy, safety, and immunogenicity of Hadlima vs Humira in patients with moderate ...

Sandoz announced the European launch of its Pyzchiva (ustekinumab) autoinjector. This is the first ustekinumab biosimilar in ...

As financial pressures intensify across health systems, Renton, Wash.-based Providence is grappling with the combined strain of high-cost therapies, slow biosimilar uptake, shrinking reimbursement and ...

Thwarted in her ambition to become a brewmaster, Kiran Mazumdar-Shaw channeled her frustrations into building a knockoff drug ...

The U.S. Food and Drug Administration (FDA) has approved STARJEMZA Injection, a biosimilar referencing Stelara (ustekinumab) Injection.

Market LaunchFormycon and Fresenius Kabi announce the commercial launch of FYB202/Otulfi™, an approved ustekinumab biosimilar in Canada 27.05.2025 / 14:30 CET/CESTThe issuer is solely responsible for ...

HADLIMA™ (adalimumab-bwwd) injection, 40 mg/0.4 mL & 40 mg/0.8 mL is now interchangeable with all high- and low-concentration presentations ...

Organon and Samsung Bioepis' HADLIMA granted FDA interchangeability designation approval for all high- and-low concentration presentations.

Lupin has signed a licence and supply agreement with SteinCares to commercialise its biosimilar ranibizumab in Latin American ...

President Donald Trump’s proposal to peg US drug prices to those paid abroad includes granting the FDA legal authority to ...